Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Study Identifies Potential New Strategy to Improve Odds of Corneal Transplant Acceptance

Published: Tuesday, December 31, 2013
Last Updated: Monday, December 30, 2013
Bookmark and Share
Study findings were reported in the December issue of the American Journal of Transplantation.

For the estimated 10 percent of patients whose bodies reject a corneal transplant, the odds of a second transplant succeeding are poor. All that could change, however, based on a UT Southwestern Medical Center study that has found a way to boost the corneal transplant acceptance rate.

In the study, researchers found that corneal transplants in mice were accepted 90 percent of the time when the action of an immune system molecule called interferon-gamma (IFN-γ) was blocked and when the mice shared the same major histocompatibility complex (MHC) genotype as the donor cornea. MHC matching is not typically done with human corneal transplants because of a high acceptance rate.

“Our findings indicate that neither MHC matching alone nor administration of anti-IFN-γ antibody alone enhances graft survival. However, we found that when MHC matching is combined with anti-IFN-γ therapy, long-term corneal transplant survival is almost guaranteed,” said Dr. Jerry Niederkorn, Professor of Ophthalmology and Microbiology at UT Southwestern and senior author of the study.

The study findings, reported in the December issue of the American Journal of Transplantation, suggest an option to improve the odds of a subsequent corneal transplant’s success for those patients whose first transplant was rejected.

More than 40,000 corneal transplants are performed annually in the United States, making this surgical procedure one of the most common and successful in transplantation. But out of that total, about 4,000 fail, with the recipient’s body rejecting the corneal graft and requiring a second operation.

A surprising finding of the study was learning that IFN-γ can act both as an immune system suppressor or activator, depending on the context of the histocompatibility antigens perceived by the immune system, Dr. Niederkorn said.

Earlier studies indicated that this molecule only activated immune system rejection of transplants and that disabling IFN-γ would improve the acceptance rate. But that was not necessarily the case; researchers found that when there was no MHC matching between the mice and the transplants, and IFN-γ was disabled, the transplant rejection rate was 100 percent.

“Under those conditions, IFN-γ was needed to maintain the T regulatory cells, which suppress the immune response,” Dr. Niederkorn said.

Rather than recommend transplant matching and inactivation of IFN-γ for all first-time corneal transplant recipients, Dr. Niederkorn said this strategy would make most sense for those who have already rejected a cornea, or for those individuals believed to be at risk for a corneal transplant rejection. But before a clinical trial can be launched to verify the results obtained in mice, further study is needed.

“We are working to develop an IFN-γ antibody in eye-drop form,” Dr. Niederkorn said. “Then we need to test whether this antibody will work in animal models.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Thursday, January 28, 2016
Enzyme Involved in Cell Division Also Plays a Role in Inflammation
NEK7 enzyme’s switch-like activity in immunity lead to new treatments for a variety of medical conditions linked to inflammation.
Thursday, December 10, 2015
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Tuesday, December 01, 2015
Researchers Identify an Enzyme as a Major Culprit of Autoimmune Diseases
Inhibition of cGAS may be an effective therapy for autoimmune diseases.
Wednesday, October 28, 2015
Boosting Gut Bacteria Defense System May Lead to Better Treatments
Life-threatening bloodstream infections reversed by enhancing a specific immune defense response.
Tuesday, June 09, 2015
Immunity Enzyme Defends Against Tuberculosis Infection
Study shows that cGAS enzyme is essential for defense against the tuberculosis bacteria.
Wednesday, June 03, 2015
Researchers Find New Mechanism That Controls Immune Responses
The findings appear online in the journal Science.
Friday, February 13, 2015
New And Beneficial Function Of Endogenous Retroviruses In Immune Response Identified
ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
Scientists Identify New and Beneficial Function of Endogenous Retroviruses
Researchers found that ERV play a critical role in the body’s immune defense against common bacterial and viral pathogens.
Friday, December 19, 2014
UT Southwestern Researcher Selected for ASBMB Merck Award
Award recognizes Dr. Zhijian Chen’s outstanding contributions to research in biochemistry and molecular biology.
Friday, July 18, 2014
Cellular Force That Drives Allergy and Asthma Can be Blocked by Interferon
Type I interferons block the development of allergy- and asthma-driving Th2 cells.
Friday, June 20, 2014
Identifying How Body Clock Affects Inflammation
UT Southwestern Medical Center researchers report that disrupting the light-dark cycle of mice increased their susceptibility to inflammatory disease.
Friday, November 08, 2013
Promising New Approach to Drug-Resistant Infections
A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings.
Wednesday, October 16, 2013
Researchers Identify New Source of Powerful Immunity Protein
New cellular source for IFN-? that keeps viruses from replicating and stimulates the immune system.
Thursday, July 11, 2013
Dr. Bruce Beutler Elected to American Academy of Arts and Sciences
AAAS has elected Nobel Laureate Dr. Beutler of UT Southwestern Medical Center to membership.
Friday, April 26, 2013
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Immune System Implicated in Gastroschisis
UCSF researchers show that the immune system is implicated in gastroschisis. The findings could lead to improved treatments for the belly birth defect.
Hay Fever's Hidden Supporting Substances
TUM study finds that non-allergenic substances in pollen heighten the immune response.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!